论文部分内容阅读
=本文最初发表于2017年《J Hematol Oncol》杂志上,文章题录为:Xu LP,Jin S,Wang SQ,et al.Uptransplant[J].J Hematol Oncol,2017,10:25。本研究在世界范围内首次报道了对多中心的连续病例进行一线单倍体移植与同期一线同胞全相合移植的疗效比较。共纳入11个移植中心的158例患者,所有进行单倍体移植的患者采用相同的移植方案,结果显示单倍型相合移植作为一线治疗与同期一线同胞全相合移植相比,3年总生存率和无失败生存率相似;多因素分析显示移植前输血量以及移植前患者的一般情况(PS评分)是影响生存的独立危险因素;所以对于具备移植条件的重型再生障碍性贫血患者,尽早采取单倍型相合移植作为一线治疗选择值得进一步研究。
This article was first published in the journal J Hematol Oncol in 2017 with the title of the article: Xu LP, Jin S, Wang SQ, et al. Uptransplant [J]. J Hematol Oncol, 2017,10: 25. This study for the first time in the world reported on the multinocular continuous cases of first-line haploidentical transplantation with the same period first-line siblings fully matched the efficacy of comparison. A total of 158 patients enrolled in 11 transplant centers and all patients undergoing haploidentical transplantation under the same transplantation protocol showed a 3-year overall survival rate as compared with haploidentical transplantation with first-line haplotype Multivariate analysis showed that the amount of blood transfusion before transplantation and the general situation before transplantation (PS score) are independent risk factors for survival; so for patients with severe aplastic anemia with transplantation, as soon as possible to take a single Multiple fold type transplantation as a first-line treatment is worth further study.